- Sernova Corp. (SVA) has reported progress on its collaboration project with Ecotec SE for its Cell Pouch device
- It has advanced Evotec’s induced pluripotent stem cells (iPSC) derived clusters in combination with the implantable Cell Pouch device to treat type-1 diabetes
- Achievements made are going towards a human phase 1/2 trial set to begin in 2024
- The trial will examine the device’s efficacy for treating patients with type-1 diabetes and severe hypoglycemia
- Sernova Corp. (SVA) is down 1.07 per cent, trading at $0.92 per share as of 2:21 p.m. EST
Sernova Corp. (SVA) has reported progress on its collaboration project with Ecotec SE for its Cell Pouch device to treat type-1 diabetes.
According to the company, this progress included the advancement of Evotec’s induced pluripotent stem cells (iPSC) derived cell-like clusters in combination with Sernova’s implantable Cell Pouch device for a first-in-human phase 1/2 clinical trial.
The trial will examine the device’s efficacy for treating patients with type-1 diabetes and severe hypoglycemia and is expected to begin in 2024.
The objective of the collaboration is to produce a commercially viable, ethically derived cell therapy treatment.
To date, the collaboration has achieved the development of a cost-efficient, scalable, highly controlled protocol with the ability to cryopreserve and store batches of differentiated cell clusters. The companies have also demonstrated excellent cluster survival under standard shipping conditions and following transplantation.
The collaboration has also shown consistent long-term insulin independence with no hypoglycemic events and consistent safety profiles in a gold-standard type-1 diabetes preclinical model. Manufacturing scale-ups and technology transfers regarding the endeavour are underway.
Sernova Corp. (SVA) is down 1.07 per cent, trading at $0.92 per share as of 2:21 p.m. EST.
